AnaptysBio, Inc. (ANAB)

Market Cap	1.49B +151.8%
Revenue (ttm)	234.60M +157.0%
Net Income	-13.23M
EPS	-0.46
Shares Out	28.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	643,270
Open	51.08
Previous Close	50.95
Day's Range	50.02 - 54.83
52-Week Range	17.11 - 73.30
Beta	0.41
Analysts	Buy
Price Target	71.91 (+38.77%)
Earnings Date	May 8, 2026

About ANAB

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2017
• Employees: 104
• Stock Exchange: NASDAQ
• Ticker Symbol: ANAB
• Website: https://www.anaptysbio.com

Financial Performance

In 2025, AnaptysBio's revenue was $234.60 million, an increase of 157.01% compared to the previous year's $91.28 million. Losses were -$13.23 million, -90.89% less than in 2024.

Analyst Summary

According to 11 analysts, the average rating for ANAB stock is "Buy." The 12-month stock price target is $71.91, which is an increase of 38.77% from the latest price.

Price Target

$71.91

(38.77% upside)

Analyst Consensus: Buy